Gratron Tablet contains Granisetron 1mg, a selective 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions. Granisetron works by blocking serotonin receptors in the central nervous system and gastrointestinal tract, thereby inhibiting the emetic signals triggered by cytotoxic agents or surgical stimuli. Gratron is indicated for patients undergoing highly emetogenic chemotherapy regimens, including those involving cisplatin, and is effective in reducing both acute and delayed phases of nausea and vomiting. The tablet formulation allows for convenient oral administration, with a recommended dosage tailored according to the emetogenic potential of the treatment and patient response. Common adverse effects may include headache, constipation, and fatigue, although the medication is generally well tolerated. Caution is advised in patients with hepatic impairment, and it should be used under medical supervision, particularly in individuals with known hypersensitivity to Granisetron or other 5-HT3 antagonists. Gratron Tablet should be stored at room temperature, away from moisture and direct sunlight, and kept out of reach of children. It is essential to follow the prescribed dosage regimen to maximize therapeutic efficacy and minimize potential side effects.